Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement" in overall survival.
Non-Small Cell Lung Cancer
Advertisement
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Expert Interviews
Advertisement
Advertisement
Section Editor
Stephen V. Liu, MDEditor | Associate Professor, Georgetown University
Advertisement
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.